$CALT News
Last published 2y ago
- 2y agoCALTCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiPR NewswireFollowing the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding...
- 2y agoCALTCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiPR NewswireFollowing the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding...
- 2y agoCALTCalliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCALTCalliditas Interim Report January to June 2024PR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, ...
- 2y agoCALTCalliditas Interim Report January to June 2024PR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, ...
- 2y agoCALTCalliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceGlobeNewswireNEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas") Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year's Women in Nephrology
- 2y agoCALTCALTXCalliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full...
- 2y agoCALTCALTXCalliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full...
- 2y agoCALTCalliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary...
- 2y agoCALTCalliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary...
- 2y agoCALTCALTXLaunch of Phase 3 clinical trial with Nefecon in JapanPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ...
- 2y agoCALTLaunch of Phase 3 clinical trial with Nefecon in JapanPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris")...
- 2y agoCALTCALTXCalliditas provides setanaxib patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office ...
- 2y agoCALTCALTXCalliditas provides setanaxib patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office ...
- 2y agoAGRAKLICALTSGEKuehn Law Encourages CALT, AKLI, AGR, and SGE Investors to Contact Law FirmGlobeNewswireNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoCALTApproval of Tarpeyo, Nda #215935 (Labeling)FDA Approved DrugsApproval Date: 06/05/2024; Drug Name: Tarpeyo, Nda #215935; Active Ingredients: BUDESONIDE; Company: Calliditas; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215935
- 2y agoCALTCALTXCalliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for...
- 2y agoCALTCALTXCalliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Data at the 61st European Renal Association CongressPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Data at the 61st European Renal Association CongressPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy...
- 2y agoCALTStatement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationPR NewswireThe Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares...
- 2y agoCALTStatement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationPR NewswireThe Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares...
- 2y agoCALTCalliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCALTCALTXIn-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day ...
- 2y agoCALTCALTXIn-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day ...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored...
- 2y agoCALTCALTXCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ...
- 2y agoCALTCALTXCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ...
- 2y agoCALTCALTXCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial...
- 2y agoCALTCALTXCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial...
- 2y agoCALTCALTXCalliditas Therapeutics' 2023 Annual Report PublishedPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available...
- 2y agoCALTCALTXCalliditas Therapeutics' 2023 Annual Report PublishedPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available...
- 2y agoCALTCALTXCalliditas Announces Positive NefIgArd Open Label Extension ResultsPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study...
- 2y agoCALTCALTXCalliditas Announces Positive NefIgArd Open Label Extension ResultsPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Conferences in AprilPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Conferences in AprilPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a...
- 2y agoCALTCALTXCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of...
- 2y agoCALTCALTXCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of...
- 2y agoCALTCALTXEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®PR NewswireEverest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)...
- 2y agoCALTCALTXCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug...
- 2y agoCALTCALTXCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Investor Conferences in MarchPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today ...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Investor Conferences in MarchPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today ...
- 2y agoCALTCALTXCalliditas provides patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office...
- 2y agoCALTCALTXCalliditas provides patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office...